The FDA is letting drugmakers recycle data from past trials to speed up gene therapies, but this regulatory shortcut places a massive burden of proof on developers.
An attention-based AI model has mapped the genetic boundaries between neurological and psychiatric diseases using nothing but raw electronic health records.
A new artificial intelligence model can classify gastric biopsies and predict lymph node spread, significantly cutting pathologist workloads without sacrificing accuracy.